CD33 Research Reagents

CD33 is a gene providing an instruction of making a protein named myeloid cell surface antigen CD33 (also abbreviated as CD33). CD33 protein, also known as SIGLEC3 or gp67, is a type I transmembrane protein exclusively expressed on immune cells, including myeloid stem cells, myeloblasts and monoblasts, monocytes/macrophages, granulocyte precursors, and mast cells. It is a 67kDa glycosylated transmembrane protein belonging to the Siglec family. After cross-linking or ligand binding, activated CD33 mediates inhibitory signals and regulates intracellular calcium mobilization, cell adhesion, leukemia cell apoptosis, myeloid cell maturation, and cytokine production.

During differentiation, CD33 is decreased on mature granulocytes but is retained on macrophages, monocytes and dendritic cells. CD33 has limited expression in non-hematopoietic tissues but is highly expressed in AML cells. In addition, CD33 has now been demonstrated to be expressed in leukemic progenitor cells, making this molecule a very promising therapeutic target for acute myelocytic leukemia (AML). At present, there are many companies developing monoclonal antibodies, double antibodies, tertiary antibodies, and ADCs targeting CD33, including Wyeth Laboratories, Seagen Inc., Sanofi, Johnson & Johnson, etc.

Popular Product

Recombinant Human Myeloid cell surface antigen CD33(CD33),partial (Active) (CSB-MP004925HU)

Validated Data

High Purity Validated by SDS-PAGE

Greater than 95% as determined by SDS-PAGE.

Excellent Bioactivity Validated by Functional ELISA

Immobilized CD33 at 2 μg/ml can bind Anti-CD33 rabbit monoclonal antibody, the EC₅₀ of human CD33 protein is 4.289- 5.312 ng/ml.